Thymic stromal lymphopoietin (TSLP) has emerged as a key target in the treatment of severe inflammatory diseases. These TSLP therapies offer a novel approach by targeting a key initiator of the inflammatory cascade. Following AstraZeneca and Amgen’s TEZSPIRE’s breakthrough approvals and a robust pipeline of emerging therapies, TSLP inhibitors are poised to revolutionize treatment for severe asthma, chronic rhinosinusitis, COPD, and beyond.
Understanding TSLP: The Master Controller of Type 2 Inflammation
Thymic stromal lymphopoietin represents a critical epithelial cytokine that sits at the top of multiple inflammatory cascades. Released from airway epithelial ce...
